Search by conditions:

 

Protocol Description Phase
14-135 A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor(FGF/FGFR)- Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors or Multiple Myeloma FGF/FGFR-Related Abnormalities  (View details on clinicaltrial.gov) Phase II
17-521 A Double-Blind, Placebo-Controlled, Randomized, Phase III Study of Ipataserib in Combination with Paclitaxel as a Treatment for Patients with PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer  (View details on clinicaltrial.gov) Phase III
17-392 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-393 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-236 A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-285 A phase 1 study of the CDK4/6 inhibitor ribociclib (LEE011) in combination with the PD-1 inhibitor PDR001 in patients with metastatic hormone receptor-positive breast cancer and metastatic ovarian cancer  (View details on clinicaltrial.gov) Phase I
17-186 A Phase 1, First-In-Human, Multi-Part Study of RAD140 in Postmenopausal Women Hormone Receptor Positive Breast Cancer  (View details on clinicaltrial.gov) Phase I
16-534 A Phase 1, Open-Label, Dose Escalation Study of Intravenous Administration of Single Agent BTP-114 in Patients with Advanced Solid Tumors and a Known Deleterious BRCA or DNA Repair Mutation  (View details on clinicaltrial.gov) Phase I
17-334 A Phase 1, Open-Label, Multicenter, Dose Escalation Study or MRNA-2416, A Lipid Nanoparticle Encapsulated MRNA Encoding Human OX4OL, For Intratumoral Injection to Patients with Advanced Malignancies  (View details on clinicaltrial.gov) Phase I
15-471 A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D)in Subjects with Advanced Breast Cancer  (View details on clinicaltrial.gov) Phase I
17-371 A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal women with estrogen receptor-positive advanced breast cancer  (View details on clinicaltrial.gov) Phase II
18-051 A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors  (View details on clinicaltrial.gov) Phase I
16-132 A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with an Antibody Targeting the PD-1/PD-L1 Pathway in HLA-A2+ Subjects Who Have Completed Initial Standard Treatment of Stage II or III Triple Negative Breast Cancer (TNBC)  (View details on clinicaltrial.gov) Phase I
17-328 A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with Pembrolizumab in HLA-A2+ Patients with Metastatic Triple Negative Breast Cancer (TNBC)  (View details on clinicaltrial.gov) Phase I
16-395 A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-472 A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients with Advanced Breast Cancer and Other Advanced Tumors Expressing HER2  (View details on clinicaltrial.gov) Phase I
16-399 A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase II
12-283 A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative Breast Cancer  (View details on clinicaltrial.gov) Phase I
13-251 A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 Genes  (View details on clinicaltrial.gov) Phase I
16-139 A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy  (View details on clinicaltrial.gov) Phase I
17-477 A Phase Ia/Ib, Multicenter, Open-label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer  (View details on clinicaltrial.gov) Phase I
13-367 A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer  (View details on clinicaltrial.gov) Phase II
16-264 A Phase II Study of Cisplatin + AZD1775 in Metastatic Triple-negative Breast Cancer and Evaluation of pCDC2 as a Biomarker of Target Response  (View details on clinicaltrial.gov) Phase II
17-603 A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment  (View details on clinicaltrial.gov) Phase II
17-431 A Phase I-II Multicenter, Open Label Trial of H3B-6545, A Covalent Antagonist of Estrogen Receptor Alpha, in Women with Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2 Negative Breast Cancer  (View details on clinicaltrial.gov) Phase II
16-577 A Randomized Phase II Study of Eribulin Mesylate With or Without Pembrolizumab for Metastatic Hormone Receptor Positive Breast Cancer  (View details on clinicaltrial.gov) Phase II
12-258 A Randomized Phase II Trial of Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide (AC) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations  (View details on clinicaltrial.gov) Phase II
17-495 An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments  (View details on clinicaltrial.gov) Phase III
16-370 An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer  (View details on clinicaltrial.gov) Phase II
17-554 An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffman-LaRoche LTD Sponsored Atezolizimab Study  (View details on clinicaltrial.gov) N/A
13-615 An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification  (View details on clinicaltrial.gov) Phase II
15-530 An Open-label, Phase Ib/II Clinical Trial of CDK 4/6 Inhibitor, Ribociclib (LEE011), in Combination with Trastuzumab or TDM-1 for Advanced/Metastatic HER2-Positive Breast Cancer  (View details on clinicaltrial.gov) Phase II
17-666 An Open-Label, Single-arm Pilot Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Localized, HER2-negative, BRCA-mutant Breast Cancer Patients  (View details on clinicaltrial.gov) N/A
16-195 Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women with ER-positive, HER2-negative Early Breast Cancer  (View details on clinicaltrial.gov) Phase II
15-488 PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer  (View details on clinicaltrial.gov) Phase III
16-150 Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers  (View details on clinicaltrial.gov) Phase I
16-501 Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects with Advanced Refractory Solid Tumor Malignancies  (View details on clinicaltrial.gov) Phase II
16-210 Phase 1b Study to Assess The Safety, Tolerability, And Clinical Activity of Gedatolisib In Combination With Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC)  (View details on clinicaltrial.gov) Phase I
17-687 Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors  (View details on clinicaltrial.gov) Phase II
15-024 Phase Ib dose-escalation trial of Taselisib (GDC-0032) in combination with anti-HER2 therapies in participants with advanced HER2+ Breast Cancer  (View details on clinicaltrial.gov) Phase I
16-423 Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)  (View details on clinicaltrial.gov) Phase I
14-056-RISK Phase II Double-Blind Randomized Controlled Trial of Naltrexone for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer  (View details on clinicaltrial.gov) Phase II
17-232 Phase II Study of CDK 4/6 Inhibitor, LEE011 (Ribociclib), in combination with Adjuvant endocrine therapy at varying Duration for ER-positive Breast Cancer (LEADER)  (View details on clinicaltrial.gov) Phase II
17-305 POLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study  (View details on clinicaltrial.gov) N/A
16-188 Pragmatic Phase III Randomized Trial of Proton Vs. Photon Therapy for Patients with Non-metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial  (View details on clinicaltrial.gov) Phase III
45 clinical trials listed

Back to Top